23andMe announces new study to help advances research in lung cancer

23andMe Holding in collaboration with 20 lung cancer advocacy organizations announced a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve detection, risk reduction, and care. “There is a great need to better define the underlying genetics of lung cancer,” said Courtney Granville, Chief Scientific Officer at GO2 for Lung Cancer. “We are privileged to stand together with the research and patient advocacy communities to contribute to this effort to better define inherited risk for lung cancer and inform our ability to prevent, diagnose, and treat people. Ultimately, the learnings from this study will improve outcomes for future generations.”